Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).

  title={Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).},
  author={Peter Hilgard and Jurij Stekar and Rainer Voegeli and J{\"u}rgen Engel and Wolfgang Schumacher and Hansjoerg Eibl and Clemens Unger and Martin R Berger},
  journal={European journal of cancer & clinical oncology},
  volume={24 9},
Hexadecylphosphocholine (HPC) differs from ether lipids with known antitumor activity by its lack of the glycerol part. In the experiments described here HPC revealed outstanding antitumor activity in dimethylbenzanthracene (DMBA)-induced rat mammary tumors. A dose-response relationship was seen after daily oral treatment with complete suppression of tumor growth at doses of 46.4 mg/kg/day. There was no schedule dependence and the therapeutic efficacy was independent of the tumor weight at the… CONTINUE READING